Back to the directory

Isabl

Cancer tests based on whole genome and transcriptome data.

Founded
2020
Status
Active
Stage
Early
Team size
5
Location
New York City, NY, USA; New York
Category
Biotech & Drug Discovery
Sector
Diagnostics

About Isabl

Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.

BiotechDiagnostics

Federal research funding

2 NIH awards totalling $2,033,377, FY2023 to FY2024.

  • Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform

Source: NIH RePORTER.

Company data compiled and maintained by Healthcare Discovery.